TD Cowen analyst Charles Rhyee lowered the firm’s price target on Amwell (AMWL) to $5 from $7 and keeps a Hold rating on the shares. The firm said Q4 EBITDA was a solid beat andd reaffirming EBITDA for 2026 is encouraging but the 20% revenue decline guidance is concerning.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell price target lowered to $5 from $6 at Stifel
- Amwell: Cost Controls and Margin Gains Offset by Weak Growth Outlook, Justifying a Hold Rating
- American Well: Strong Near-Term Performance but Limited Post-2026 Visibility Keeps Rating at Hold
- Amwell reports Q4 EPS ($1.52), consensus ($1.60)
- Amwell sees Q1 revenue $48M-53M, consensus $57.82M